Elsevier

Seminars in Immunology

Volume 30, April 2017, Pages 36-44
Seminars in Immunology

Review
Oral immunotherapy for food allergy

https://doi.org/10.1016/j.smim.2017.08.008Get rights and content

Abstract

Food allergy is a pathological, potentially deadly cascade of immune responses to molecules or molecular fragments that are normally innocuous when encountered in foods, such as milk, egg, or peanut. As the incidence and prevalence of food allergy rise, the standard of care is poised to advance beyond food allergen avoidance coupled with injectable epinephrine treatment of allergen-induced systemic reactions. Recent studies provide evidence that oral immunotherapy may effectively redirect the atopic immune responses of food allergy patients as they ingest small but gradually increasing allergen doses over many months, eliciting safer immune responses to these antigens. Research into the molecular and cellular bases of pathological and therapeutic immune responses, and into the possibilities for their safe and effective modulation, is generating tremendous interest in basic and clinical immunology. We synthesize developments, innovations, and key challenges in our understanding of the immune mechanisms associated with atopy and oral immunotherapy for food allergy.

Introduction

Food allergy affects 8% of children and 5% of adults in the U.S. [1], [2], and epidemiological data generally indicate an increase in its prevalence [2]. However, the current standard of care for all food allergies is minimal, consisting of food-allergen avoidance and emergency treatment of potentially fatal allergen-induced systemic reactions with injectable epinephrine; the constant risk of severe allergic reaction adversely impacts the quality of life of food-allergy patients and their families. The growing, global, unmet need for safe and effective treatment can best be met by understanding the cellular and molecular mechanisms of promising immunotherapeutic approaches under clinical investigation [3].

The mechanistic role of IgE in atopic immune responses provides a useful distinction among types of food allergy: IgE-mediated food allergy is characterized by acute, potentially life-threatening immune responses, while non-IgE-mediated food allergy is driven by slower, cell-mediated responses. This review focuses on IgE-mediated food allergy, in which food allergen epitopes bind to IgE molecules which also bind FcεRI receptors on immune effector cells, such as basophils, mast cells, and antigen-presenting dendritic cells. Epitope-specific crosslinking of the IgE-bound receptors results in degranulation of basophils and mast cells, releasing pre-formed histamine and other inflammatory molecules that generate a rapid atopic reaction [4]. Additional inflammatory mediators, such as platelet activating factor, leukotrienes and the cytokines interleukin-4 (IL-4), IL-5, and IL-13, are then produced de novo, augmenting the inflammatory immune response [4]. Membrane-bound IgE on B cells also forms a complex with CD23 and CD21, increasing production of soluble IgE [5] and escalating the IgE-mediated immune response. The resulting symptoms may include gastrointestinal responses (e.g., pruritus, abdominal pain, nausea, vomiting), respiratory responses (e.g., airway inflammation, wheezing), dermal responses (e.g., pruritus, angioedema, urticaria), and systemic responses (e.g., hypotension, hypothermia). An anaphylactic response involves multiple organ systems and rapidly may become life-threatening [6].

Recent clinical studies reviewed here provide evidence that oral immunotherapy (OIT) can be used safely and effectively to reduce the sensitivity of food allergy (FA) patients to food antigens (Ag). However, it is not yet clear the extent to which such patients develop desensitization (DS, defined as a lack of clinical reactivity to Ag, the maintenance of which requires regular Ag exposure), as distinct from sustained unresponsiveness (SU), in which the patient exhibits a long-term and perhaps permanent loss of reactivity to Ag that is independent of continued Ag exposure. Novel findings from our group and others are elucidating the mechanisms by which DS and SU are established through OIT.

In OIT, FA study participants ingest small but gradually increasing doses of specific food Ag over the course of several months, with the goal of progressively retraining their immune responses to establish DS and possibly SU to the Ag (Fig. 1) [7]. Because other FA diagnostic tools, such as measurements of blood levels of Ag-specific IgE and skin-prick tests, are known to generate false positives that could confound research results [8], [9], an initial, definitive FA diagnosis is made using a double-blind, placebo-controlled, oral food challenge (DBPCFC) with one or more target Ag. On the first day of OIT, the participant ingests increasing doses of the target Ag under clinical care to determine the highest tolerated dose. After this initial-day dose escalation, the highest tolerated dose is used to begin a dose-escalation phase, in which the dose is increased in a visit to the clinic every 1–2 weeks until the designated maintenance dose is tolerated. Then, during the maintenance phase which ranges from months to years, the participant daily ingests the maintenance dose of the FA. A desensitization DBPCFC is administered in the clinic at the end of the maintenance phase, to assess the efficacy of the treatment protocol. If a statistically significant increase in the tolerated dose to a level that is protective against accidental Ag exposure is found, the OIT is deemed successful. DS, or a reduction in adverse immune response that is maintained through regular Ag exposure, is often achieved through OIT, along with lower risk of anaphylaxis and increased quality of life for FA participants and their families.

To test for SU, an Ag avoidance phase of weeks to months may be added after the termination of OIT, ending with a followup DBPCFC. If the target dose is tolerated after the avoidance phase, the participant has achieved SU to that dose, a reduced immune response to Ag that persists even without continued, regular Ag exposure. Since a DBPCFC is not prospective, the duration and variance of SU are unknown. The mechanisms underlying SU, its potential durability and defeat, and its comparison to healthy tolerance are promising research areas that could be of tremendous benefit to our understanding of healthy, atopic, and therapy-induced immune states.

The field of FA OIT is very active and growing. This review focuses on recent, peer-reviewed studies, prioritizing phase II trials with a placebo arm, clearly defined dosing, and those that required a screening DBPCFC (sDBPCFC) to avoid confounding due to false positive FA diagnoses. We also prioritize studies with associated, long-term followup to assess SU, and associated mechanistic studies. We highlight recent advances in the safety, efficacy, and mechanistic understanding of OIT.

Section snippets

Immune mechanisms

The immunological mechanisms of: (1) the establishment and maintenance of a healthy state of immune tolerance to food antigens; (2) food allergy; and (3) desensitization established through OIT are drawing increasing research interest. The evolution of this research is addressed in several recent reviews [10], [11], [12], [13], [14], [15], [16]; key features are outlined here. While we focus on food allergy research in humans, we also cite relevant hypotheses based on research in closely

OIT

OIT trials are very valuable resources for the study of the cellular and molecular mechanisms by which FA pathology and treatment are effected. For example, a pilot study to examine the role of invariant natural killer T cells (iNKT) in OIT was performed with 11 highly allergic children having a history of anaphylaxis to cow’s milk and a positive sDBPCFC [68]. An open course of lactose-free cow’s milk OIT was given, with antihistamine and with a protocol for temporary dose reduction during

Further mechanistic insights

Mechanistic studies of different immune cell subsets during short- and long-term courses of OIT are important to perform, to try to discover new targets for rational drug design in food allergy in the future. For example, a study was recently published using peripheral blood mononuclear cells (PBMCs) from 21 peanut-allergic (PA) individuals and 7 healthy controls to determine whether functional peanut-specific type 1 regulatory T cells (Tr1), which are potent immune response suppressors, could

Conclusion

As oral immunotherapy advances the management and prevention of food allergy, research aimed at its molecular and cellular mechanisms advances our understanding of healthy, pathological, and therapeutic human immune responses. Innovations to extend the safety and efficacy of OIT prominently include the use of blocking antibodies as adjuvants to OIT, interfering with various effector pathways that otherwise could bring about the clinical manifestations of IgE-mediated atopic immune response.

Acknowledgements

The authors would like to thank Vanitha Sampath for creating Fig. 2, Fig. 3, Fig. 4 and the bibliography. This work was supported by NIH grant U19AI104209, the Bezos Family Foundation, the FARE Center of Excellence, the Myra Reinhard Foundation, and the Sean N. Parker Center for Allergy and Asthma Research at Stanford University.

References (94)

  • J. Farache et al.

    Luminal bacteria recruit CD103+ dendritic cells into the intestinal epithelium to sample bacterial antigens for presentation

    Immunity

    (2013)
  • E. Mazzini et al.

    Oral tolerance can be established via gap junction transfer of fed antigens from CX3CR1(+) macrophages to CD103(+) dendritic cells

    Immunity

    (2014)
  • G. Marelli et al.

    Non-redundant role of the chemokine receptor CX3CR1 in the anti-inflammatory function of gut macrophages

    Immunobiology

    (2017)
  • B. Cassani et al.

    Gut-tropic T cells that express integrin alpha4beta7 and CCR9 are required for induction of oral immune tolerance in mice

    Gastroenterology

    (2011)
  • G. Gri et al.

    CD4+CD25+ regulatory T cells suppress mast cell degranulation and allergic responses through OX40-OX40L interaction

    Immunity

    (2008)
  • U. Hadis et al.

    Intestinal tolerance requires gut homing and expansion of FoxP3+ regulatory T cells in the lamina propria

    Immunity

    (2011)
  • W. Yao et al.

    Interleukin-9 is required for allergic airway inflammation mediated by the cytokine TSLP

    Immunity

    (2013)
  • M. Noval Rivas et al.

    Regulatory T cell reprogramming toward a Th2-cell-like lineage impairs oral tolerance and promotes food allergy

    Immunity

    (2015)
  • S.J. Van Dyken et al.

    Chitin activates parallel immune modules that direct distinct inflammatory responses via innate lymphoid type 2 and gammadelta T cells

    Immunity

    (2014)
  • T.Y.F. Halim et al.

    Group 2 innate lymphoid cells are critical for the initiation of adaptive T helper 2 cell-mediated allergic lung inflammation

    Immunity

    (2014)
  • W. van de Veen et al.

    IgG4 production is confined to human IL-10–producing regulatory B cells that suppress antigen-specific immune responses

    J. Allergy Clin. Immunol.

    (2013)
  • A.F. Santos et al.

    IgG4 inhibits peanut-induced basophil and mast cell activation in peanut-tolerant children sensitized to peanut major allergens

    J. Allergy Clin. Immunol.

    (2015)
  • M. Akdis et al.

    Mechanisms of allergen-specific immunotherapy: multiple suppressor factors at work in immune tolerance to allergens

    J. Allergy Clin. Immunol.

    (2014)
  • L.A. Beck et al.

    Omalizumab-induced reductions in mast cell FcepsilonRI expression and function

    J. Allergy Clin. Immunol.

    (2004)
  • C. Prussin et al.

    Omalizumab treatment downregulates dendritic cell FcepsilonRI expression

    J. Allergy Clin. Immunol.

    (2003)
  • T.W. Chang et al.

    Anti-IgE antibodies for the treatment of IgE-mediated allergic diseases

    Adv. Immunol.

    (2007)
  • P. Zieglmayer et al.

    Mechanisms, safety and efficacy of a B cell epitope-based vaccine for immunotherapy of grass pollen allergy

    EBioMedicine

    (2016)
  • M. Londei et al.

    A phase 1 study of ANB020, an anti-IL-33 monoclonal antibody in healthy volunteers

    J. Allergy Clin. Immunol.

    (2017)
  • A.H. Assa'ad et al.

    An antibody against IL-5 reduces numbers of esophageal intraepithelial eosinophils in children with eosinophilic esophagitis

    Gastroenterology

    (2011)
  • R.S. Gupta et al.

    The prevalence, severity, and distribution of childhood food allergy in the United States

    Pediatrics

    (2011)
  • S.H. Sicherer et al.

    Food allergy: epidemiology, pathogenesis, diagnosis, and treatment

    J. Allergy Clin. Immunol.

    (2014)
  • K.D. Stone et al.

    IgE, mast cells, basophils, and eosinophils

    J. Allergy Clin. Immunol.

    (2010)
  • J.D. Wright et al.

    Structural and physical basis for anti-IgE therapy

    Nat. Sci. Rep.

    (2015)
  • J.D. Kattan et al.

    Allergen component testing for food allergy: ready for prime time?

    Curr. Allergy Asthma Rep.

    (2013)
  • M. Wawrzyniak et al.

    Role of regulatory cells in oral tolerance

    Allergy Asthma Immunol Res.

    (2017)
  • W. Yu et al.

    Food allergy: immune mechanisms, diagnosis and immunotherapy

    Nat. Rev. Immunol.

    (2016)
  • R. Valenta et al.

    Food allergies: the basics

    Gastroenterology

    (2015)
  • K. Hirota et al.

    Plasticity of Th17 cells in Peyer’s patches is responsible for the induction of T cell-dependent IgA responses

    Nat. Immunol.

    (2013)
  • H. Lelouard et al.

    Peyer's patch dendritic cells sample antigens by extending dendrites through M cell-specific transcellular pores

    Gastroenterology

    (2012)
  • J.L. Coombes et al.

    A functionally specialized population of mucosal CD103+ DCs induces Foxp3+ regulatory T cells via a TGF-beta and retinoic acid-dependent mechanism

    J. Exp. Med.

    (2007)
  • E.K. Persson et al.

    Dendritic cell subsets in the intestinal lamina propria: ontogeny and function

    Eur. J. Immunol.

    (2013)
  • C.M. Sun et al.

    Small intestine lamina propria dendritic cells promote de novo generation of Foxp3 T reg cells via retinoic acid

    J. Exp. Med.

    (2007)
  • H.L. Weiner et al.

    Oral tolerance

    Immunol. Rev.

    (2011)
  • M. Murai et al.

    Interleukin 10 acts on regulatory T cells to maintain expression of the transcription factor Foxp3 and suppressive function in mice with colitis

    Nat. Immunol.

    (2009)
  • L. Tordesillas et al.

    Skin exposure promotes a Th2-dependent sensitization to peanut allergens

    J. Clin. Invest.

    (2014)
  • H. Han et al.

    The atopic march: current insights into skin barrier dysfunction and epithelial cell-derived cytokines

    Immunol. Rev.

    (2017)
  • D. Venkataraman et al.

    Filaggrin loss-of-function mutations are associated with food allergy in childhood and adolescence

    J. Allergy Clin. Immunol.

    (2014)
  • Cited by (30)

    • Notch signaling contributes to the establishment of sustained unresponsiveness to food allergens by oral immunotherapy

      2021, Journal of Allergy and Clinical Immunology
      Citation Excerpt :

      It is unclear whether SU induced by OIT and oral tolerance occurring via natural development represent the same state. In the induction of oral tolerance, antigen-specific Foxp3+ Treg cells in the intestinal LP play an important role.23 The development of Treg cells is induced by antigen presentation by CD103+ dendritic cells to naive CD4+ T cells in the lymph nodes and is promoted by TGF-β and retinoic acid produced by the dendritic cells.31

    • Vaccines as therapies for food allergies

      2021, Advances in Pharmacology
      Citation Excerpt :

      These studies have demonstrated that as the period of allergen avoidance after AIT increases, the rate of sustained unresponsiveness decreases (Vickery et al., 2014). Protocols for OIT for other foods are being developed, including ongoing clinical trials and in clinical practice without FDA approval (Freeland et al., 2017; Wasserman et al., 2019). Further study is needed to refine protocols for food AIT and determine markers to indicate continued desensitization or induction of tolerance.

    • Slow low-dose oral immunotherapy: Threshold and immunological change

      2020, Allergology International
      Citation Excerpt :

      In contrast, sublingual immunotherapy5,8 and epicutaneous immunotherapy9 have been reported for their safety profiles and acceptable efficacies. Therefore instead of sustained unresponsiveness, recent clinical studies report that OIT can be used safely and effectively to reduce the sensitivity of FA.10 This can improve the quality of life of patients and their family11 and possibly result in long-term sustained unresponsiveness.12

    View all citing articles on Scopus
    View full text